PHILIP SEIBLER

PERSONAL INFORMATION

Position/Title: Research Group Leader (Institute of Neurogenetics)

Address University of Lübeck; Ratzeburger Allee 160, 23538 Lübeck, Germany

Tel: +49-451-31018212; Fax: +49-451-31018204

@: philip.seibler@neuro.uni-luebeck.de; www.neurogenetics-luebeck.de

EDUCATION/POSITIONS

2001-2006 Studies of Molecular Life Sciences (University of Lübeck)

2006 Master Thesis (Prof. C. Klein, Institute of Neurogenetics)

2006-2011 PhD Studies (Prof. C. Klein, Institute of Neurogenetics)

2011 PhD Thesis: summa cum laude

2009-2010 Research Fellow (Prof. Dimitri Krainc, MD, PhD), MassGeneral Institute for Neurodegenerative Disease, Harvard Medical School, Boston, USA

2011-2012 Postdoctoral researcher at the Institute of Neurogenetics, University of Lübeck

2013-2016 Research Group Leader “Human Neurons Derived from Induced Pluripotent Stem Cells” at the Institute of Neurogenetics, University of Lübeck

2016-2017 Research Fellow (Prof. Matthew Farrer, PhD), Centre for Applied Neurogenetics, University of British Columbia, Vancouver, Canada

2017-2019 Professor of Applied Stem Cell Biology (W2), University of Lübeck

2019-present Research Group Leader of Applied Stem Cell Biology at the Institute of Neurogenetics, University of Lübeck

ACADEMIC ACTIVITIES

2015-present Ad hoc reviewer for >7 journals (e.g. Neurobiology of Disease, Annals of Neurology, Scientific Reports, Frontiers Cellular Neuroscience)

2017-present Member of the Scientific Advisory Board of the EU-funded SysMedPD consortium

2018-present Member of the Federal Cluster of Excellence Program “Precision Medicine in Chronic Inflammation” (PMI)

AWARDS

2009 DAAD Graduate student fellowship, Harvard Medical School, USA

2011 Young Investigator Award of the German Society of Neurogenetics

2014 “Sparkasse zu Lübeck AG” Founders Award

2015 DFG Research Fellowship, University of British Columbia, Canada

SELECTED PUBLICATIONS

From 33 original publications; total citations: 1,297; h-index: 15

      1. Seibler P (equally contributing first author), Djarmati A, Langpap B, Hagenah J, Schmidt A, Brüggemann N, Siebner H, Jabusch HC, Altenmüller E, Münchau A, Lohmann K, Klein C. A heterozygous frameshift mutation in PRKRA (DYT16) associated with generalised dystonia in a German patient. Lancet Neurol 2008;7:380-381. [IF: 14.3]
      2. Rakovic A, Grünewald A, Seibler P, Ramirez A, Kock N, Orolicki S, Lohmann K, Klein C. Effect of endogenous mutant and wild-type PINK1 on Parkin in fibroblasts from Parkinson disease patients. Hum Mol Genet 2010;19:3124-3137. [IF: 8.1]
      3. Seibler P, Graziotto J, Jeong H, Simunovic F, Klein C, Krainc D. Mitochondrial Parkin Recruitment Is Impaired in Neurons Derived from Mutant PINK1 Induced Pluripotent Stem Cells. J Neurosci 2011;31:5970-5976.
        [IF: 7.1]
      4. Morais VA, Haddad D, Craessaerts K, De Bock P-J, Swerts J, Vilain S, Aerts L, Overbergh L, Grünewald A, Seibler P, Klein C, Gevaert K, Verstreken P, De Strooper B. PINK1 loss of function mutations affect Complex I activity via NdufA10 ubiquinone uncoupling. Science 2014;344:203-207. [IF: 33.6]
      5. Vulinovic F, Lohmann K, Rakovic A, Capetian P, Alvarez-Fischer D, Schmidt A, Weißbach A, Erogullari A, Kaiser FJ, Wiegers K, Ferbert A, Rolfs A, Klein C, Seibler P. Unraveling cellular phenotypes of novel TorsinA/TOR1A mutations. Hum Mutat 2014;35:1114-1122. [IF: 5.1]
      6. Munsie LN, Milnerwood AJ, Seibler P (equally contributing first author), Beccano-Kelly DA, Tatarnikov I, Khinda J, Volta M, Kadgien C, Cao LP, Tapia L, Klein C, Farrer MJ. Retromer-dependent neurotransmitter receptor trafficking to synapses is altered by the Parkinson’s Disease VPS35 mutation p.D620N. Hum Mol Genet 2015;24:1691-703. [IF: 6.4]
      7. Zanon A, Kalvakuri S, Rakovic A, Foco L, Guida M, Schwienbacher C, Serafin A, Rudolph F, Trilck M, Grünewald A, Stanslowsky N, Wegner F, Giorgio V, Lavdas AA, Bodmer R, Pramstaller PP, Klein C, Hicks AA, Pichler I, Seibler P (equally contributing senior author). SLP-2 interacts with Parkin in mitochondria and prevents mitochondrial dysfunction in Parkin-deficient human iPSC-derived neurons and Drosophila. Hum Mol Genet. 2017;26:2412-2425. [IF: 5.3]
      8. Valadas JS, Esposito G, Vandekerkhove D, Miskiewicz K, Deaulmerie L, Raitano S, Seibler P, Klein C, Verstreken P. ER Lipid Defects in Neuropeptidergic Neurons Impair Sleep Patterns in Parkinson’s Disease. Neuron 2018;98:1155-1169. [IF: 14.4]
      9. Baumann H, Jahn M, Muenchau A, Trilck-Winkler M, Lohmann K, Seibler P (equally contributing senior author). Generation and characterization of eight human-derived iPSC lines from affected and unaffected THAP1 mutation carriers. Stem Cell Res. 2018;33:60-64. [IF: 3.9]
      10. Seibler P (equally contributing first author), Burbulla LF, Dulovic M, Zittel S, Heine J, Schmidt T, Rudolph F, Westenberger A, Rakovic A, Münchau A, Krainc D, Klein C. Iron overload is accompanied by mitochondrial and lysosomal dysfunction in WDR45 mutant cells. Brain 2018;141:3052-3064. [Editor’s Choice] [IF: 11.8]